Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • ascls.org
    • ascls.org

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society for Clinical Laboratory Science
  • ascls.org
    • ascls.org
  • My alerts
  • Log in
  • My Cart
American Society for Clinical Laboratory Science

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • Follow ASCLS on Twitter
  • Visit ASCLS on Facebook
  • Follow ASCLS on Instagram
  • RSS Feed
Research ArticleFocus: Pseudomonas Aeruginosa

Treatment Strategies and Recommendations for Pseudomonas aeruginosa Infections

Nicholas M. Moore and Maribeth L. Flaws
American Society for Clinical Laboratory Science January 2011, 24 (1) 52-56; DOI: https://doi.org/10.29074/ascls.24.1.52
Nicholas M. Moore
Rush University, Department of Medical Laboratory Science, Chicago, IL
MS, MLS(ASCP)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Nicholas_Moore@rush.edu
Maribeth L. Flaws
Rush University, Department of Medical Laboratory Science, Chicago, IL
PhD, SM(ASCP)SI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

  1. Nicholas M. Moore, MS, MLS(ASCP)⇑
    1. Rush University, Department of Medical Laboratory Science, Chicago, IL
  2. Maribeth L. Flaws, PhD, SM(ASCP)SI
    1. Rush University, Department of Medical Laboratory Science, Chicago, IL
  1. Address for Correspondence: Nicholas M. Moore, MS, MLS (ASCP), Department of Medical Laboratory Science, 600 S. Paulina St., Suite 1014, Chicago, IL 60612, 312-942-2111, Fax: (312) 942-6464, Nicholas_Moore{at}rush.edu
  1. Describe the mechanism of action of the primary anti-pseudomonal agents.

  2. List the advantages and disadvantages of combination drug therapy.

  3. List the advantages and disadvantages of mono drug therapy.

  4. Determine which antibiotic combinations are appropriate for treatment of various infections caused by Pseudomonas aeruginosa.

Extract

Pseudomonas aeruginosa is a common cause of infection, especially hospital-acquired infections. It is opportunistic, more often causing infection in immunocom-promised hosts and it is often antibiotic resistant, complicating the efficacy of therapy. These factors have increased the number of patients infected with P. aeruginosa, increased the severity of those infections, and caused a great deal of conflict amongst infectious disease practitioners on how to appropriately and effectively manage their treatment. The following sections will describe appropriate treatment regimens for non-cystic fibrosis patients with infections caused by P. aeruginosa and discuss empiric as well as mono versus combination therapy protocols.

Anti-Pseudomonas Antibiotics The antimicrobial agents listed in Table 1 have activity against P. aeruginosa.

Beta Lactams Beta-lactams are a broad group of antibiotics that include penicillins, cephalosporins, monobactams and carbapenems. At the molecular level, the beta-lactams have thiazolidine and beta-lactam rings to which is attached a side chain. Beta-lactams are one of the most widely prescribed antibiotic agents in the United States. They are bactericidal and act by binding to transpeptidases [also known as penicillin-binding proteins (PBP)] thereby interfering with the synthesis of the peptidoglycan layer of the cell wall. Bacteria, including P. aeruginosa, become resistant to beta-lactams by either possessing enzymes (beta-lactamases) that hydrolyze the beta-lactam ring or altering the PBPs such that the antimicrobial agent can no longer bind and exert its effect.

The beta-lactams that have the most activity against P. aeruginosa include piperacillin, ticarcillin, 3rd and 4th generation cephalosporins (ceftazidime and cefepime respectfully), and carbapenems like imipenem…

ABBREVIATIONS: DNA = Deoxyribonucleic Acid, IDSA = Infectious Disease Society of America, ATS = American Thoracic Society.

    INDEX TERMS
  • Pseudomonas aeruginosa
  • anti-Pseudomonas antibiotics
  • Beta Lactams
  1. Describe the mechanism of action of the primary anti-pseudomonal agents.

  2. List the advantages and disadvantages of combination drug therapy.

  3. List the advantages and disadvantages of mono drug therapy.

  4. Determine which antibiotic combinations are appropriate for treatment of various infections caused by Pseudomonas aeruginosa.

  • © Copyright 2011 American Society for Clinical Laboratory Science Inc. All rights reserved.
PreviousNext
Back to top

In this issue

American Society for Clinical Laboratory Science: 24 (1)
American Society for Clinical Laboratory Science
Vol. 24, Issue 1
Winter 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Society for Clinical Laboratory Science.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treatment Strategies and Recommendations for Pseudomonas aeruginosa Infections
(Your Name) has sent you a message from American Society for Clinical Laboratory Science
(Your Name) thought you would like to see the American Society for Clinical Laboratory Science web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Treatment Strategies and Recommendations for Pseudomonas aeruginosa Infections
Nicholas M. Moore, Maribeth L. Flaws
American Society for Clinical Laboratory Science Jan 2011, 24 (1) 52-56; DOI: 10.29074/ascls.24.1.52

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Treatment Strategies and Recommendations for Pseudomonas aeruginosa Infections
Nicholas M. Moore, Maribeth L. Flaws
American Society for Clinical Laboratory Science Jan 2011, 24 (1) 52-56; DOI: 10.29074/ascls.24.1.52
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Epidemiology and Pathogenesis of Pseudomonas aeruginosa Infections
  • Antimicrobial Resistance Mechanisms in Pseudomonas aeruginosa
Show more Focus: Pseudomonas Aeruginosa

Similar Articles

Keywords

  • Pseudomonas aeruginosa
  • anti-Pseudomonas antibiotics
  • Beta Lactams

© 2025 The American Society for Clinical Laboratory Science

Powered by HighWire